RecruitingNot ApplicableNCT05631405

Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)

Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone

Sponsor

Chulalongkorn University

Enrollment

200 participants

Start Date

Oct 16, 2022

Study Type

INTERVENTIONAL

Conditions

Severe Dengue

Summary

The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.

Eligibility

Min Age: 7 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dexamethasone and a drug called Placebo for people with severe dengue. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 7 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone

Patients treated with dexamethasone

DRUGPlacebo

Patients treated with placebo

Locations(2)

Chulalongkorn University

Bangkok, Thailand

King Chulalongkorn Memorial Hospital

Bangkok, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05631405

Related Trials

Innovative Multidisciplinary Strategies for Combating Severe Dengue

NCT067518362 locations